2024 Biologics and Advanced Therapies Contract Manufacturing Report

Download the 2024 Biologics and Advanced Therapies Contract Manufacturing Report for an in-depth look into the current industry trends and analysis of the competitive dynamics in North America and Europe.

Key Highlights:

• The global CDMO biologics and advanced therapies market contracted by 17% in 2023. A rebound is expected by late 2025, fueled by increased global production of branded and biosimilar drugs.
• Large and medium-sized CDMOs account for 89% of total revenue. Small and micro-manufacturers represent most market participants and contribute 11% of overall revenue.
• In 2023, cell and gene therapies saw a record number of FDA approvals and innovations, with eight therapies approved despite challenging market conditions, compared to five in both 2022 and 2021. These breakthroughs mark a new phase for transformative therapies nearing commercialization. As production scales up, significant growth is anticipated in the advanced therapies CDMO market.